Description
Tesamorelin supplied as a 10 mg lyophilised powder in a sealed vial. Identifiers, analytical methods and storage conditions for this 10 mg presentation are listed below; the certificate for the lot shipped carries the measured values.
Specification
| Compound | Tesamorelin |
|---|---|
| Nominal content | 10 mg |
| Physical form | Lyophilised powder |
| CAS number | 218949-48-5 |
| PubChem CID | 16137828 |
| Molecular formula | C221H366N72O67S |
| Molecular weight (free base) | 5135.86 g/mol |
| Residue count | 44 |
| Purity method | RP-HPLC |
| Identity method | Mass spectrometry |
| Purity, net peptide content and counterion | As stated on the lot certificate |
| Appearance | White to off-white lyophilised solid |
| Storage | -20 °C, desiccated, protected from light |
| Shipping | Ambient; lyophilised for transit stability |
Identity and nomenclature
Acetate salt CAS 901758-09-6. Residue-level sequence not published here; see the lot certificate.
Analysis and documentation
Each lot is assayed by an independent laboratory. Purity is determined by reversed-phase HPLC and reported as the main peak as a percentage of total peak area. Identity is confirmed by mass spectrometry, comparing the observed mass against the theoretical mass for the formula above. The certificate for the lot shipped states the purity figure, the net peptide content, the counterion and the date of analysis.
Handling and storage
Store the sealed vial at -20 °C, desiccated and protected from light. Allow the vial to reach room temperature before opening, so that atmospheric moisture does not condense onto the lyophilised solid. Lyophilised material is shipped at ambient temperature.
Research use only
Supplied for in-vitro laboratory research. Not for human or veterinary use, and not for diagnostic or therapeutic use of any kind. Not evaluated by the FDA.
